Business Update

AIDS vaccine, neuroscience drug developer discusses corporate milestones

Published in AIDS Weekly, February 13th, 2006

CytRx Corp. (CYTR) announced projected major 2006 clinical and corporate milestones and reviewed 2005 achievements aimed to advance the company's goal to develop and commercialize human therapeutics, primarily in the area of small molecules and ribonucleic acid interference (RNAi).

CytRx's 2005 highlights include:

1) Completed enrollment in HIV DNA + protein vaccine phase I clinical trial.

2) Received orphan drug status designation from the U.S. Food and Drug Administration (FDA) for arimoclomol in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig disease).

3) Filed an investigational new drug...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2006-02-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry